Aviv Regev

Computational and systems biologist Aviv Regev focuses on developing and applying experimental methods and computational algorithms to decipher intra- and intercellular circuits in cells in tissues. She is a pioneer of single cell genomics and has leveraged advances in technology to generate new insights in fields including immunology, neurobiology and cancer.

Regev is currently the Head of Genentech Research and Early Development (gRED), where she is responsible for all aspects of gRED’s drug discovery and development. Regev is also a member of the Genentech Executive Committee and Board of Directors, and a member of the expanded Corporate Executive Committee for Roche.

Prior to Genentech, Regev served as Professor of Biology at MIT, and Chair of the Faculty, Core Institute Member, Founding Director of the Klarman Cell Observatory, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as an Investigator at the Howard Hughes Medical Institute. Regev is a founding co-chair of the Human Cell Atlas.